ACUT — Accustem Sciences Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1850767 ·
Last close
$0.27
Market Cap
$4.34M
52W High
$0.51
52W Low
$0.26
ADV30
1,272
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -485,883 | -485,883 | 1,549,532 | 12,207 | 5,421,879 |
| Dec 2025 | 0 | — | -514,388 | -514,388 | 1,549,446 | 13,929 | 4,951,071 |
| Sep 2025 | 0 | — | -399,897 | -399,897 | 1,573,247 | 14,391 | 4,484,157 |
| Jun 2025 | 0 | — | -401,403 | -401,403 | 1,613,537 | 31,341 | 4,148,224 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-850,389
Investing CF
$0
Financing CF
$859,271
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.10
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,783,143
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-1,756,096
Pretax Income TTM
$-1,756,096
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,756,096 | -1,756,096 | 1,549,446 | 4,951,071 | — | -850,389 |
| Dec 2024 | 0 | -1,505,102 | -1,505,102 | 50,851 | 3,364,075 | — | -664,066 |
| Dec 2023 | 0 | -2,050,664 | -2,050,664 | 133,897 | 2,245,477 | — | -1,615,643 |
| Dec 2022 | 0 | -3,746,419 | -3,746,419 | 939,689 | 1,079,239 | — | -1,806,053 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALZN | Alzamend Neuro, Inc. | $4.38M | $1.15 | — |
| CDT | CDT Equity Inc. | $4.30M | $0.88 | — |
| MBIO | MUSTANG BIO, INC. | $4.19M | $0.62 | — |
| ENSC | Ensysce Biosciences, Inc. | $4.52M | $0.31 | — |
| GELS | Gelteq Ltd | $4.52M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
2026-01-08 12:00 · Yahoo
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
2025-09-18 12:35 · Yahoo
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
2025-09-17 11:00 · Yahoo
Life Science Virtual Investor Forum Agenda Announced for September 18th
2025-09-16 15:57 · Yahoo
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
2025-09-16 11:00 · Yahoo
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
2025-06-16 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.